erlotinib hydrochloride has been researched along with Cancer of the Vulva in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Burandt, E; Coym, A; Hillen, C; Jaeger, A; Kuerti, S; Mathey, S; Mueller, V; Prieske, K; Schmalfeldt, B; Woelber, L | 1 |
Bacha, OM; Lalancette, M; Levesque, E; Renaud, MC | 1 |
Borger, DR; Brard, L; Dizon, DS; Growdon, WB; Horowitz, NS; Krasner, CN; Lee, J; Liu, JF; Matulonis, UA; Olawaiye, AB | 1 |
Horowitz, N; Krasner, C; Lee, LM; Olawaiye, A | 1 |
1 review(s) available for erlotinib hydrochloride and Cancer of the Vulva
Article | Year |
---|---|
Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunotherapy; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A; Vulvar Neoplasms | 2021 |
1 trial(s) available for erlotinib hydrochloride and Cancer of the Vulva
Article | Year |
---|---|
Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Vulvar Neoplasms | 2012 |
2 other study(ies) available for erlotinib hydrochloride and Cancer of the Vulva
Article | Year |
---|---|
A case of recurrent vulvar carcinoma treated with erlotinib, an EGFR inhibitor.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Quinazolines; Vulvar Neoplasms | 2011 |
Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva.
Topics: Aged; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Vulvar Neoplasms | 2007 |